IFN-γ-induced chemokines synergize with pertussis toxin to promote T cell entry to the central nervous system

Journal of Immunology

Volumn 178, Issue 12, 2007, Pages 8175-8182

  Millward, Jason M ^a,b   Caruso, Maria ^a   Campbell, Iain L ^c   Gauldie, Jack ^d   Owens, Trevor ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE; CXCL2 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA INTERFERON RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PERTUSSIS TOXIN; RANTES; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE ADHERENCE; IMMUNOASSAY; IMMUNOSURVEILLANCE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; T LYMPHOCYTE;

EID: 34250213712     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.12.8175     Document Type: Article

References (59)

1. Casetta, I., and E. Granieri. 2000. Prognosis of multiple sclerosis: environmental factors. Neurol. Sci. 21: S839-S842.
2. Buljevac, D., H. Z. Flach, W. C. Hop, D. Hijdra, J. D. Laman, H. F. Savelkoul, F. G. van Der Meché, P. A. van Doorn, and R. Q. Hintzen. 2002. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125: 952-960.
3. Compston, A., and A. Coles. 2002. Multiple sclerosis. Lancet 359: 1221-1231.
4. Lee, J. M., and P. K. Olitsky. 1955. Simple method for enhancing development of acute disseminated encephalomyelitis in mice. Proc. Soc. Exp. Biol. Med. 89: 263-266.
5. Linthicum, D. S., J. J. Munoz, and A. Blaskett. 1982. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell. Immunol. 73: 299-310.
6. Yong, T., G. A. Meininger, and D. S. Linthicum. 1993. Enhancement of histamine-induced vascular leakage by pertussis toxin in SJL/J mice but not BALB/c mice. J. Neuroimmunol. 45: 47-52.
7. Farrar, M. A., and R. D. Schreiber. 1993. The molecular cell biology of interferon-γ and its receptor. Annu. Rev. Immunol. 11: 571-611.
8. Simmons, R. D., and D. O. Willenborg. 1990. Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation. J. Neurol. Sci. 100: 37-42.
9. Sethna, M. P., and L. A. Lampson. 1991. Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-κ. J. Neuroimmunol. 34: 121-132.
10. Renno, T., V. Taupin, L. Bourbonniere, G. Verge, E. Tran, R. De Simone, M. Krakowski, M. Rodriguez, A. Peterson, and T. Owens. 1998. Interferon-κ in progression to chronic demyelination and neurological deficit following acute EAE. Mol. Cell. Neurosci. 12: 376-389.
11. LaFerla, F. M., M. C. Sugarman, T. E. Lane, and M. A. Leissring. 2000. Regional hypomyelination and dysplasia in transgenic mice with astrocyte-directed expression of interferon-γ. J. Mol. Neurosci. 15: 45-59.
12. Horwitz, M. S., C. F. Evans, D. B. McGavern, M. Rodriguez, and M. B. Oldstone. 1997. Primary demyelination in transgenic mice expressing interferon-γ. Nat. Med. 3: 1037-1041.
13. Corbin, J. G., D. Kelly, E. M. Rath, K. D. Baerwald, K. Suzuki, and B. Popko. 1996. Targeted CNS expression of interferon-γ in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol. Cell. Neurosci. 7: 354-370.
14. Voorthuis, J. A., B. M. Uitdehaag, C. J. De Groot, P. H. Goede, P. H. van der Meide, and C. D. Dijkstra. 1990. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-γ in Lewis rats. Clin. Exp. Immunol. 81: 183-188.
15. Furlan, R., E. Brambilla, F. Rullini, P. L. Poliani, A. Bergami, P. C. Marconi, D. M. Franciotta, G. Penna, G. Comi, L. Adorini, and G. Martino. 2001. Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167: 1821-1829.
16. Lublin, F. D., R. L. Knobler, B. Kalman, M. Goldhaber, J. Marini, M. Perrault, C. D'Imperio, J. Joseph, S. S. Alkan, and R. Korngold. 1993. Monoclonal anti-γ interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 16: 267-274.
17. Duong, T. T., J. St. Louis, J. J. Gilbert, F. D. Finkelman, and G. H. Strejan. 1992. Effect of anti-interferon-γ and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J. Neuroimmunol. 36: 105-115.
18. Billiau, A., H. Heremans, F. Vandekerckhove, R. Dijkmans, H. Sobis, H. Meulepas, and H. Carton. 1988. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J. Immunol. 140: 1506-1510.
19. Duong, T. T., F. D. Finkelman, B. Singh, and G. H. Strejan. 1904. Effect of anti-interferon-γ monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains. J. Neuroimmunol. 53: 101-107.
20. Ferber, I. A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, and C. G. Fathman. 1996. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156: 5-7.
21. Krakowski, M., and T. Owens. 1996. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26: 1641-1646.
22. Willenborg, D. O., S. Fordham, C. C. Bernard, W. B. Cowden, and I. A. Ramshaw. 1996. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157: 3223-3227.
23. Tran, E. H., F. N. Prince, and T. Owens. 2000. IFN-γ shapes immune invasion of the central nervous system via regulation of chemokines. J. Immunol. 164: 2759-2768.
24. Glabinski, A. R., M. Krakowski, Y. Han, T. Owens, and R. M. Ransohoff. 1999. Chemokine expression in GKO mice (lacking interferon-γ) with experimental autoimmune encephalomyelitis. J. Neurovirol. 5: 95-101.
25. Godiska, R., D. Chantry, G. N. Dietsch, and P. W. Gray. 1995. Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 58: 167-176.
26. Martino, G., R. Furlan, G. Comi, and L. Adorini. 2001. The ependymal route to the CNS: an emerging gene-therapy approach for MS. Trends Immunol. 22: 483-490.
27. Flügel, A., G. Hager, A. Horvat, C. Spitzer, G. M. Singer, M. B. Graeber, G. W. Kreutzberg, and F. W. Schwaiger. 2001. Neuronal MCP-1 expression in response to remote nerve injury. J. Cereb. Blood Flow Metab. 21: 69-76.
28. Babcock, A. A., W. A. Kuziel, S. Rivest, and T. Owens. 2003. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci. 23: 7922-7930.
29. Hausmann, E. H., N. E. Berman, Y. Y. Wang, J. B. Meara, G. W. Wood, and R. M. Klein. 1998. Selective chemokine mRNA expression following brain injury. Brain Res. 788: 49-59.
30. Otto, V. I., P. F. Stahel, M. Rancan, K. Kariya, E. Shohami, I. Yatsiv. H. P. Eugster, T. Kossmann, O. Trentz, and M. C. Morganti-Kossmann. 2001. Regulation of chemokines and chemokine receptors after experimental closed head injury. Neuroreport 12: 2059-2064.
31. Zehntner, S. P., C. Brickman, L. Bourbonniere, L. Remington, M. Caruso, and T. Owens. 2005. Neutrophils that infiltrate the central nervous system regulate T cell responses. J. Immunol. 174: 5124-5131.
32. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-γ receptor. Science 259: 1742-1745.
33. Furlan, R., S. Pluchino, P. C. Marconi, and G. Martino. 2003. Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors. Methods Mol. Biol. 215: 279-289.
34. + T cells. J. Immunol. 162: 2890-2894.
35. Liu, M. T., H. S. Keirstead, and T. E. Lane. 2001. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J. Immunol. 167: 4091-4097.
36. Glass, W. G., M. J. Mickey, J. L. Hardison, M. T. Liu, J. E. Manning, and T. F. Lane. 2004. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J. Immunol. 172: 4018-4025.
37. Toft-Hansen, H., R. K. Nullah, D. R. Edwards, and T. Owens. 2004. Key metalloproleinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J. Immunol. 173: 5209-5218.
38. Strack, A., V. C. Asensio, I. L. Campbell, D. Schluter, and M. Deckert. 2002. Chemokines are differentially expressed by astrocytes, microglia and inflammatory leukocytes in Toxoplasma encephalitis and critically regulated by interferon-γ. Acta Neuropathol. 103: 458-468.
39. + T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA 96: 6873-6878.
40. Miyagishi, R., S. Kikuchi, C. Takayama, Y. Inoue, and K. Tashiro. 1997. Identification of cell types producing RANTES. MIP-1α: and MIP-1β in rat experimental autoimmune encephalomyelitis by in situ hybridization. J. Neuroimmunol. 11: 17-26.
41. Sedgwick, J. D., S. Schwender, H. Imrich, R. Dorries, G. W. Butcher, and V. ter Meulen. 1901. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl. Acad. Sci. USA 88: 7438-7442.
42. Brabb, T., P. von Dassow, N. Ordonez, B. Schnabel, B. Duke, and J. Goverman. 2000. In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity. J. Exp. Med. 192: 871-880.
43. Ohmori, Y., and T. A. Hamilton. 1993. Cooperative interaction between interferon (IFN) stimulus response element and κB sequence motifs controls IFN κ-and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. J. Biol. Chem. 268: 6677-6688.
44. Liu, J., X. Guan, and X. Ma. 2005. Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon γ-induced RANTES/CCI5 expression in macrophages. J. Biol. Chem. 280: 24347-24355.
45. Murphy, C. A., R. M. Hoek, M. T. Wiekowski, S. A. Lira, and J. D. Sedgwick. 2002. Interactions hetween hemopoietically derived TNK and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain. J. Immunol. 169: 7054-7062.
46. Boztug, K., M. J. Carson, N. Pham-Mitchell, V. C. Asensio, J. DeMartino, and I. L. Campbell. 2002. Leukocyte infiltration, but not neurodegeneration, in the CNS of transgenic mice with astrocyte production of the CXC chemokine ligand 10. J. Immunol. 169: 1505-1515.
47. Fuentes, M. E., S. K. Durham, M. R. Swerdel, A. C. Lewin, D. S. Barton, J. R. Megill, R. Bravo, and S. A. Lira. 1905. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J. Immunol. 155: 5769-5776.
48. 4X. Huang, D., M. Tani, J. Wang, Y. Han, T. T. He, J. Weaver, I. F. Charo, V. K. Tuohy, B. J. Rollins, and R. M. Ransohoff. 2002. Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice. J. Neurosci. 22: 10633-10642.
49. Laflamme, N., and S. Rivest. 2001. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating Gram-negative bacterial cell wall components. FASEB J. 15: 155-163.
50. Goverman, J., A. Woods, L. Larson, L. P. Weiner, L. Hood, and D. M. Zaller. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72: 551-560.
51. Blankenhorn, E. P., R. J. Butterfield, R. Rigby, L. Cort, D. Giambrone, P. McDermott, K. McEntee, N. Solowski, N. D. Meeker, J. F. Zachary, et al. 2000. Genetic analysis of the influence of pertussis toxin on experimental allergic encephalomyelitis susceptibility: an environmental agent can override genetic-checkpoints. J. Immunol. 164: 3420-3425.
52. Kerfoot, S. M., E. M. Long, M. J. Hickey, G. Andonegui, B. M. Lapointe. R. C. Zanardo, C. Bonder, W. G. James, S. M. Robbins, and P. Kubes. 2004. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol. 173: 7070-7077.
53. Waldner, H., M. Collins, and V. K. Kuchroo. 2004. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113: 990-997.
54. Kong, A. S., and S. I. Morse. 1977. The in vitro effects of Bordetella pertussis lymphocytosis-promoting factor on murine lymphocytes. I. Proliferative response. J. Exp. Med. 145: 151-162.
55. Morse, J. H., A. S. Kong, J. Lindenbaum, and S. I. Morse. 1977. The mitogenic effect of the lymphocytosis promoting factor from Bordetella pertussis on human lymphocytes. J. Clin. Invest. 60: 683-692.
56. Ryan, M., L. McCarthy, R. Rappuoli, B. P. Mahon, and K. H. Mills. 1998. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int. Immunol. 10: 651-662.
57. Kamradt, T., P. D. Soloway, D. L. Perkins, and M. L. Gefter. 1991. Pertussis toxin prevents the induction of peripheral T cell anergy and enhances the T cell response to an encephalitogenic peptide of myelin basic protein. J. Immunol. 147: 3296-3302.
58. Sewell, W. A., J. J. Munoz, and M. A. Vadas. 1983. Enhancement of the intensity, persistence, and passive transfer of delayed-type hypersensitivity lesions by pertussigen in mice. J. Exp. Med. 157: 2087-2096.
59. Sewell, W. A., J. J. Munoz, R. Scollay, and M. A. Vadas. 1984. Studies on the mechanism of the enhancement of delayed-type hypersensitivity by pertussigen. J. Immunol. 133: 1716-1722.